Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCL001 in Decompensated Cirrhosis
NCT06306781Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
01
Overview
Open-label, single-arm trial of allogeneic hepatocyte in decompensated cirrhosis, sponsored by Renji Hospital. Primary endpoints: Types and incidence of treatment-related adverse events at 48 weeks, Dose-Limiting Toxicity at 28 days and 1 more. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
allogeneic hepatocyte
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on NCT06306781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306781.